| Market Cap | 2B | P/E | - | EPS this Y | -17.60% | Ern Qtrly Grth | - |
| Income | -153.3M | Forward P/E | -11.57 | EPS next Y | -23.30% | 50D Avg Chg | -3.00% |
| Sales | 33.05M | PEG | -0.43 | EPS past 5Y | - | 200D Avg Chg | -22.00% |
| Dividend | N/A | Price/Book | 1.66 | EPS next 5Y | 10.00% | 52W High Chg | -54.00% |
| Recommedations | 1.90 | Quick Ratio | 10.49 | Shares Outstanding | 294.67M | 52W Low Chg | 25.00% |
| Insider Own | 28.05% | ROA | -11.41% | Shares Float | 188.55M | Beta | 0.37 |
| Inst Own | 41.51% | ROE | -13.30% | Shares Shorted/Prior | 16.84M/18.17M | Price | 6.94 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 3,156,685 | Target Price | 15.43 |
| Oper. Margin | -1,276.17% | Earnings Date | Nov 4 | Volume | 2,224,034 | Change | -4.54% |
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Montalbano John S. | Director Director | Nov 06 | Buy | 4.55 | 30,000 | 136,500 | 86,000 | 11/08/23 |
| Hayden Michael R | Director Director | Sep 22 | Buy | 4.91 | 20,000 | 98,200 | 1,323,397 | 09/26/23 |
| Lecault Veronique | Chief Operating Offi.. Chief Operating Officer | Sep 12 | Buy | 5.19 | 20,000 | 103,800 | 2,040,122 | 09/14/23 |
| Hayden Michael R | Director Director | Aug 08 | Buy | 5.90 | 30,000 | 177,000 | 1,303,397 | 08/09/23 |
| Booth Andrew | Chief Financial Offi.. Chief Financial Officer | Dec 20 | Option | 0.19 | 50,000 | 9,500 | 188,500 | 12/22/22 |
| Thermopylae Holdings Ltd. | 10% Owner 10% Owner | Dec 16 | Buy | 10.0967 | 85,102 | 859,249 | 55,859,493 | 12/20/22 |
| Hansen Carl L. G. | Chief Executive Offi.. Chief Executive Officer | Nov 18 | Option | 2.70 | 56,125 | 151,538 | 449,000 | 11/21/22 |
| Thermopylae Holdings Ltd. | 10% Owner 10% Owner | Aug 19 | Buy | 11.4623 | 200,000 | 2,292,460 | 55,844,391 | 08/22/22 |
| Hansen Carl L. G. | Chief Executive Offi.. Chief Executive Officer | Aug 18 | Option | 2.70 | 56,125 | 151,538 | 392,875 | 08/22/22 |
| Thermopylae Holdings Ltd. | 10% Owner 10% Owner | Jun 13 | Buy | 8.04 | 64,088 | 515,268 | 55,644,391 | 06/15/22 |
| Thermopylae Holdings Ltd. | 10% Owner 10% Owner | Jun 06 | Buy | 7.4981 | 64,545 | 483,965 | 55,580,303 | 06/08/22 |
| Hansen Carl L. G. | Chief Executive Offi.. Chief Executive Officer | May 18 | Option | 2.70 | 56,125 | 151,538 | 336,750 | 05/19/22 |
| Lecault Veronique | Chief Operating Offi.. Chief Operating Officer | May 16 | Buy | 6.3389 | 200,000 | 1,267,780 | 1,770,122 | 05/17/22 |
| Thermopylae Holdings Ltd. | 10% Owner 10% Owner | May 13 | Buy | 7.2551 | 300,000 | 2,176,530 | 55,515,758 | 05/17/22 |
| Montalbano John S. | Director Director | Mar 01 | Buy | 9.05 | 20,000 | 181,000 | 46,000 | 03/03/22 |
| Lecault Veronique | Chief Operating Offi.. Chief Operating Officer | Feb 28 | Buy | 8.66 | 230,789 | 1,998,633 | 1,570,122 | 03/01/22 |
| Hansen Carl L. G. | Chief Executive Offi.. Chief Executive Officer | Feb 22 | Option | 2.70 | 56,125 | 151,538 | 280,625 | 02/25/22 |
| Booth Andrew | Chief Financial Offi.. Chief Financial Officer | Nov 11 | Buy | 14.68 | 67,500 | 990,900 | 130,959 | 11/15/21 |